{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:24:33Z","timestamp":1794644673415,"version":"4.9.1"},"publisher-location":"Cham","reference-count":162,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030742881","type":"print"},{"value":"9783030742898","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/112_2020_50","type":"book-chapter","created":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T05:02:52Z","timestamp":1601096572000},"page":"31-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!"],"prefix":"10.1007","author":[{"given":"Vajir","family":"Malek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin V.","family":"Suryavanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant R.","family":"Mulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,27]]},"reference":[{"key":"50_CR1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","volume":"46","author":"H Abuissa","year":"2005","unstructured":"Abuissa H, Jones PG, Marso SP, O\u2019Keefe JH (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821\u2013826","journal-title":"J Am Coll Cardiol"},{"key":"50_CR2","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12:2032\u20132045","journal-title":"Clin J Am Soc Nephrol"},{"key":"50_CR3","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcibr1608564","volume":"375","author":"HJ Anders","year":"2016","unstructured":"Anders HJ, Davis JM, Thurau K (2016) Nephron protection in diabetic kidney disease. N Engl J Med 375:2096\u20132098","journal-title":"N Engl J Med"},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.vph.2013.01.001","volume":"58","author":"MK Arora","year":"2013","unstructured":"Arora MK, Singh UK (2013) Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol 58:259\u2013271","journal-title":"Vascul Pharmacol"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14656566.8.5.529","volume":"8","author":"VG Athyros","year":"2007","unstructured":"Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A (2007) Angiotensin II reactivation and aldosterone escape phenomena in renin\u2013angiotensin\u2013aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 8:529\u2013535","journal-title":"Expert Opin Pharmacother"},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","volume":"74","author":"G Bakris","year":"2008","unstructured":"Bakris G, Burgess E, Weir M, Davidai G, Koval S (2008) Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74:364\u2013369","journal-title":"Kidney Int"},{"key":"50_CR7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314:884\u2013894","journal-title":"JAMA"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","volume":"352","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B, Messerli FH (2016) Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. Br Med J 352:i438","journal-title":"Br Med J"},{"key":"50_CR9","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"A Barnett","year":"2004","unstructured":"Barnett A (2004) Diabetics exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952\u20131961","journal-title":"N Engl J Med"},{"key":"50_CR10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.21037\/atm.2016.05.24","volume":"4","author":"JI Barzilay","year":"2016","unstructured":"Barzilay JI, Whelton PK, Davis BR (2016) Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes? Ann Transl Med 4:202\u2013208","journal-title":"Ann Transl Med"},{"key":"50_CR11","doi-asserted-by":"crossref","first-page":"H666","DOI":"10.1152\/ajpheart.00372.2006","volume":"292","author":"IF Benter","year":"2007","unstructured":"Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI (2007) Angiotensin-(1\u20137) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292:H666\u2013H672","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/HJH.0000000000002378","volume":"38","author":"AE Berbari","year":"2020","unstructured":"Berbari AE (2020) Angiotensin receptor neprolysin inhibitors: a novel approach to prevent cardiorenal disease in diabetes mellitus. J Hypertens 38:608\u2013609","journal-title":"J Hypertens"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20110036","volume":"121","author":"S Bosnyak","year":"2011","unstructured":"Bosnyak S, Jones ES, Christopoulos A, Aguilar M-I, Thomas WG, Widdop RE (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci 121:297\u2013303","journal-title":"Clin Sci"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 345:861\u2013869","journal-title":"New Engl J Med"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/bph.13044","volume":"172","author":"E Bruce","year":"2015","unstructured":"Bruce E, Shenoy V, Rathinasabapathy A, Espejo A, Horowitz A, Oswalt A et al (2015) Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br J Pharmacol 172:2219\u20132231","journal-title":"Br J Pharmacol"},{"key":"50_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-med-052914-091923","volume":"67","author":"A Buglioni","year":"2016","unstructured":"Buglioni A, Burnett JC Jr (2016) New pharmacological strategies to increase cGMP. Annu Rev Med 67:229\u2013243","journal-title":"Annu Rev Med"},{"key":"50_CR17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.hjh.0000191244.91314.9d","volume":"24","author":"M Burnier","year":"2006","unstructured":"Burnier M, Zanchi A (2006) Blockade of the renin\u2013angiotensin\u2013aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24:11\u201325","journal-title":"J Hypertens"},{"key":"50_CR18","doi-asserted-by":"crossref","first-page":"H324","DOI":"10.1152\/ajpheart.1989.257.1.H324","volume":"257","author":"MJ Campagnole-Santos","year":"1989","unstructured":"Campagnole-Santos MJ, Diz DI, Santos R, Khosla MC, Brosnihan KB, Ferrario CM (1989) Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol Heart Circ Physiol 257:H324\u2013H329","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1043-2760(03)00111-5","volume":"14","author":"RM Carey","year":"2003","unstructured":"Carey RM, Siragy HM (2003) The intrarenal renin\u2013angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 14:274\u2013281","journal-title":"Trends Endocrinol Metab"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.kint.2019.04.024","volume":"96","author":"P Cassis","year":"2019","unstructured":"Cassis P, Locatelli M, Corna D, Villa S, Rottoli D, Cerullo D et al (2019) Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. Kidney Int 96:906\u2013917","journal-title":"Kidney Int"},{"key":"50_CR21","doi-asserted-by":"crossref","first-page":"F1123","DOI":"10.1152\/ajprenal.00247.2014","volume":"307","author":"G Castoldi","year":"2014","unstructured":"Castoldi G, di Gioia CR, Bombardi C, Maestroni S, Carletti R, Steckelings UM et al (2014) Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 307:F1123\u2013F1131","journal-title":"Am J Physiol Renal Physiol"},{"key":"50_CR22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.peptides.2011.09.010","volume":"32","author":"AND Cat","year":"2011","unstructured":"Cat AND, Touyz RM (2011) A new look at the renin\u2013angiotensin system \u2013 focusing on the vascular system. Peptides 32:2141\u20132150","journal-title":"Peptides"},{"key":"50_CR23","doi-asserted-by":"publisher","unstructured":"Chang Y, Chen YW, Chenier I, Tran SLM, Zhang SL (2011) Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res. https:\/\/doi.org\/10.1155\/2011\/521076","DOI":"10.1155\/2011\/521076"},{"key":"50_CR24","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/ijms19041006","volume":"19","author":"Y Chen","year":"2018","unstructured":"Chen Y, Burnett JC (2018) Particulate guanylyl cyclase A\/cGMP signaling pathway in the kidney: physiologic and therapeutic indications. Int J Mol Sci 19:1006\u20131018","journal-title":"Int J Mol Sci"},{"key":"50_CR25","doi-asserted-by":"publisher","unstructured":"Chen X-W, Du X-Y, Wang Y-X, Wang J-C, Liu W-T, Chen W-J et al (2016) Irbesartan ameliorates diabetic nephropathy by suppressing the RANKL-RANK-NF-\u03baB pathway in type 2 diabetic db\/db mice. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2016\/1405924","DOI":"10.1155\/2016\/1405924"},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amjms.2018.01.017","volume":"355","author":"Y Chen","year":"2018","unstructured":"Chen Y, Liu P, Chen X, Li Y, Zhang F, Wang Y (2018) Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. Am J Med Sci 355:418\u2013424","journal-title":"Am J Med Sci"},{"key":"50_CR27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/01.hjh.0000179765.48324.b4","volume":"23","author":"ZJ Cheng","year":"2005","unstructured":"Cheng ZJ, Gr\u00f6nholm T, Louhelainen M, Finckenberg P, Merasto S, Tikkanen I et al (2005) Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats. J Hypertens 23:1757\u20131770","journal-title":"J Hypertens"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"N Cho","year":"2018","unstructured":"Cho N, Shaw J, Karuranga S, Huang Y, da Rocha FJ, Ohlrogge A et al (2018) IDF diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271\u2013281","journal-title":"Diabetes Res Clin Pract"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1042\/CS20160243","volume":"130","author":"BS Chow","year":"2016","unstructured":"Chow BS, Allen TJ (2016) Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. Clin Sci 130:1307\u20131326","journal-title":"Clin Sci"},{"key":"50_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.1976.56.1.1","volume":"56","author":"J Davis","year":"1976","unstructured":"Davis J, Freeman R (1976) Mechanisms regulating renin release. Physiol Rev 56:1\u201356","journal-title":"Physiol Rev"},{"key":"50_CR31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/14746514060060010301","volume":"6","author":"P De","year":"2006","unstructured":"De P, Das G, Harley K, Nair H (2006) Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience. Br J Diabetes Vasc Dis 6:23\u201328","journal-title":"Br J Diabetes Vasc Dis"},{"key":"50_CR32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2012.4604","volume":"19","author":"SI Dikalov","year":"2013","unstructured":"Dikalov SI, Nazarewicz RR (2013) Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal 19:1085\u20131094","journal-title":"Antioxid Redox Signal"},{"key":"50_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-019-0304-z","volume":"20","author":"K Dizaye","year":"2019","unstructured":"Dizaye K, Ali RH (2019) Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure. BMC Pharmacol Toxicol 20:1\u20137","journal-title":"BMC Pharmacol Toxicol"},{"key":"50_CR34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N et al (2000) A novel angiotensin-converting enzyme\u2013related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:e1\u2013e9","journal-title":"Circ Res"},{"key":"50_CR35","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ncpendmet0894","volume":"4","author":"S Dronavalli","year":"2008","unstructured":"Dronavalli S, Duka I, Bakris GL (2008) The pathogenesis of diabetic nephropathy. Nat Rev Endocrinol 4:444\u2013452","journal-title":"Nat Rev Endocrinol"},{"key":"50_CR36","doi-asserted-by":"crossref","first-page":"R494","DOI":"10.1152\/ajpregu.00487.2011","volume":"302","author":"B Ellis","year":"2011","unstructured":"Ellis B, Li XC, Miguel-Qin E, Gu V, Zhuo JL (2011) Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney. Am J Physiol Regul Integr Comp Physiol 302:R494\u2013R509","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"50_CR37","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew V Jr, Martinez F, Altamirano J, Roniker B, Kleiman J et al (2002) OR-54: antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 15:24A","journal-title":"Am J Hypertens"},{"key":"50_CR38","doi-asserted-by":"crossref","unstructured":"Esser N, Zraika S (2019) Neprilysin inhibition: a new therapeutic option for type 2 diabetes? Diabetologia:1\u201310","DOI":"10.1007\/s00125-019-4889-y"},{"key":"50_CR39","doi-asserted-by":"crossref","first-page":"12049","DOI":"10.1073\/pnas.192404199","volume":"99","author":"Y-H Feng","year":"2002","unstructured":"Feng Y-H, Sun Y, Douglas JG (2002) G\u03b2\u03b3-independent constitutive association of G\u03b1s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1. Proc Natl Acad Sci 99:12049\u201312054","journal-title":"Proc Natl Acad Sci"},{"key":"50_CR40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/01.HYP.0000047512.58862.A9","volume":"41","author":"A Forclaz","year":"2003","unstructured":"Forclaz A, Maillard M, Nussberger JR, Brunner HR, Burnier M (2003) Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 41:31\u201336","journal-title":"Hypertension"},{"key":"50_CR41","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. New Engl J Med 369:1892\u20131903","journal-title":"New Engl J Med"},{"key":"50_CR42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","volume":"29","author":"M Frimodt-M\u00f8ller","year":"2020","unstructured":"Frimodt-M\u00f8ller M, Persson F, Rossing P (2020) Mitigating risk of aldosterone in diabetic kidney disease. Curr Opin Nephrol Hypertens 29:145\u2013151","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"50_CR43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajpath.2013.03.025","volume":"183","author":"E Gagliardini","year":"2013","unstructured":"Gagliardini E, Perico N, Rizzo P, Buelli S, Longaretti L, Perico L et al (2013) Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1\/Snail pathway. Am J Pathol 183:119\u2013130","journal-title":"Am J Pathol"},{"key":"50_CR44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/dom.12630","volume":"18","author":"H Gallagher","year":"2016","unstructured":"Gallagher H, Suckling R (2016) Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab 18:641\u2013647","journal-title":"Diabetes Obes Metab"},{"key":"50_CR45","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3892\/ijmm.2016.2525","volume":"37","author":"F Gao","year":"2016","unstructured":"Gao F, Yao M, Cao Y, Liu S, Liu Q, Duan H (2016) Valsartan ameliorates podocyte loss in diabetic mice through the Notch pathway. Int J Mol Med 37:1328\u20131336","journal-title":"Int J Mol Med"},{"key":"50_CR46","doi-asserted-by":"crossref","first-page":"36A","DOI":"10.1016\/S0895-7061(00)00385-X","volume":"13","author":"R Garcia-Robles","year":"2000","unstructured":"Garcia-Robles R, Villabla F, Gonzalez-Albarran O, G\u00f3mez O, R\u00e1bano A, Ruilope L et al (2000) Effects of omapatrilat on blood pressure and the progression of renal failure in an experimental model of type II diabetes mellitus. Am J Hypertens 13:36A\u201336A","journal-title":"Am J Hypertens"},{"key":"50_CR47","doi-asserted-by":"crossref","first-page":"F1606","DOI":"10.1152\/ajprenal.00063.2012","volume":"302","author":"JF Giani","year":"2012","unstructured":"Giani JF, Burghi V, Veiras LC, Tomat A, Mu\u00f1oz MC, Cao G et al (2012) Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 302:F1606\u2013F1615","journal-title":"Am J Physiol Renal Physiol"},{"key":"50_CR48","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/bph.13946","volume":"174","author":"SK Goru","year":"2017","unstructured":"Goru SK, Kadakol A, Malek V, Pandey A, Sharma N, Gaikwad AB (2017) Diminazene aceturate prevents nephropathy by increasing glomerular Ace2 and At2 receptor expression in a rat model of type1 diabetes. Br J Pharmacol 174:3118\u20133130","journal-title":"Br J Pharmacol"},{"key":"50_CR49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-019-0847-8","volume":"18","author":"J Habibi","year":"2019","unstructured":"Habibi J, Aroor AR, Das NA, Manrique-Acevedo CM, Johnson MS, Hayden MR et al (2019) The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat. Cardiovasc Diabetol 18:40","journal-title":"Cardiovasc Diabetol"},{"key":"50_CR50","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/med.21449","volume":"38","author":"M Hallberg","year":"2018","unstructured":"Hallberg M, Sumners C, Steckelings UM, Hallberg A (2018) Small-molecule AT2 receptor agonists. Med Res Rev 38:602\u2013624","journal-title":"Med Res Rev"},{"key":"50_CR51","first-page":"128","volume":"7","author":"HJ Heerspink","year":"2019","unstructured":"Heerspink HJ, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL et al (2019) Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet 7:128\u2013139","journal-title":"Lancet"},{"key":"50_CR52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/CS20060342","volume":"112","author":"S Higuchi","year":"2007","unstructured":"Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S (2007) Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci 112:417\u2013428","journal-title":"Clin Sci"},{"key":"50_CR53","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","volume":"37","author":"J Hou","year":"2015","unstructured":"Hou J, Xiong W, Cao L, Wen X, Li A (2015) Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther 37:2086\u20132103.e2010","journal-title":"Clin Ther"},{"key":"50_CR54","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/978-3-319-93521-8_29","volume-title":"Diabetic nephropathy","author":"NM Idzerda","year":"2019","unstructured":"Idzerda NM, Pena MJ, de Zeeuw D, Heerspink HJ (2019) Future and novel compounds in the treatment of diabetic nephropathy. In: Diabetic nephropathy. Springer, New York, pp 515\u2013539"},{"key":"50_CR55","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/hr.2009.74","volume":"32","author":"M Iwai","year":"2009","unstructured":"Iwai M, Horiuchi M (2009) Devil and angel in the renin\u2013angiotensin system: ACE\u2013angiotensin II\u2013AT1 receptor axis vs. ACE2\u2013angiotensin-(1\u20137)\u2013Mas receptor axis. Hypertens Res 32:533\u2013536","journal-title":"Hypertens Res"},{"key":"50_CR56","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","volume":"24","author":"D Jennings","year":"2007","unstructured":"Jennings D, Kalus J, Coleman C, Manierski C, Yee J (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 24:486\u2013493","journal-title":"Diabet Med"},{"key":"50_CR57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2550","volume":"7","author":"C Jensen","year":"2008","unstructured":"Jensen C, Herold P, Brunner HR (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 7:399\u2013410","journal-title":"Nat Rev Drug Discov"},{"key":"50_CR58","doi-asserted-by":"crossref","first-page":"24543","DOI":"10.1016\/S0021-9258(19)74499-8","volume":"268","author":"Y Kambayashi","year":"1993","unstructured":"Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T et al (1993) Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268:24543\u201324546","journal-title":"J Biol Chem"},{"key":"50_CR59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11892-009-0074-x","volume":"9","author":"YS Kang","year":"2009","unstructured":"Kang YS, Cha DR (2009) Aldosterone and diabetic kidney disease. Curr Diab Rep 9:453\u2013459","journal-title":"Curr Diab Rep"},{"key":"50_CR60","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00125-007-0795-9","volume":"50","author":"D Kelly","year":"2007","unstructured":"Kelly D, Zhang Y, Moe G, Naik G, Gilbert R (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50:2398\u20132404","journal-title":"Diabetologia"},{"key":"50_CR61","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.108.146431","volume":"328","author":"LD Kluskens","year":"2009","unstructured":"Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y et al (2009) Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther 328:849\u2013854","journal-title":"J Pharmacol Exp Ther"},{"key":"50_CR62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E (2004) Omapatrilat and enalapril in patients with hypertension: the Omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17:103\u2013111","journal-title":"Am J Hypertens"},{"key":"50_CR63","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/HYPERTENSIONAHA.115.05204","volume":"65","author":"C Koulis","year":"2015","unstructured":"Koulis C, Chow BS, McKelvey M, Steckelings UM, Unger T, Thallas-Bonke V et al (2015) AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension 65:1073\u20131081","journal-title":"Hypertension"},{"key":"50_CR64","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms19061712","volume":"19","author":"SM Krishnan","year":"2018","unstructured":"Krishnan SM, Kraehling JR, Eitner F, B\u00e9nardeau A, Sandner P (2018) The impact of the nitric oxide (NO)\/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective. Int J Mol Sci 19:1712\u20131730","journal-title":"Int J Mol Sci"},{"key":"50_CR65","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ejhf.896","volume":"20","author":"SL Kristensen","year":"2018","unstructured":"Kristensen SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, Ali MA, Shao Q et al (2018) Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. Eur J Heart Fail 20:136\u2013147","journal-title":"Eur J Heart Fail"},{"key":"50_CR66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin\u2013angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30\u201348","journal-title":"Ann Intern Med"},{"key":"50_CR67","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.intimp.2014.05.027","volume":"21","author":"S Kuriakose","year":"2014","unstructured":"Kuriakose S, Uzonna JE (2014) Diminazene aceturate (Berenil), a new use for an old compound? Int Immunopharmacol 21:342\u2013345","journal-title":"Int Immunopharmacol"},{"key":"50_CR68","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/10715762.2011.560149","volume":"45","author":"AP Lakshmanan","year":"2011","unstructured":"Lakshmanan AP, Watanabe K, Thandavarayan RA, Sari FR, Harima M, Giridharan VV et al (2011) Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1\u20137) mas receptor expression associated with its PPAR-\u03b3 agonist action. Free Radic Res 45:575\u2013584","journal-title":"Free Radic Res"},{"key":"50_CR69","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1046\/j.1523-1755.2000.07715.x","volume":"58","author":"DJ Leehey","year":"2000","unstructured":"Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy. Kidney Int 58:S93\u2013S98","journal-title":"Kidney Int"},{"key":"50_CR70","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New Engl J Med 329:1456\u20131462","journal-title":"New Engl J Med"},{"key":"50_CR71","first-page":"617","volume":"19","author":"J Li","year":"2005","unstructured":"Li J, Culman J, H\u00f6rtnagl H, Zhao Y, Gerova N, Timm M et al (2005) Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19:617\u2013619","journal-title":"FASEB J"},{"key":"50_CR72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1751-7141.2008.00010.x","volume":"12","author":"PR Liebson","year":"2009","unstructured":"Liebson PR, Amsterdam EA (2009) Ongoing Telmisartan alone and in combination with Ramipril global endpoint trial (ONTARGET): implications for reduced cardiovascular risk. Prev Cardiol 12:43\u201350","journal-title":"Prev Cardiol"},{"key":"50_CR73","first-page":"59","volume":"17","author":"CX Liu","year":"2011","unstructured":"Liu CX, Hu Q, Wang Y, Zhang W, Ma ZY, Feng JB et al (2011) Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med 17:59\u201369","journal-title":"Mol Med"},{"key":"50_CR74","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-030-16481-2_10","volume-title":"Textbook of vascular medicine","author":"SM MacKenzie","year":"2019","unstructured":"MacKenzie SM, Cat AND, van Kralingen JC, Davies E (2019) Aldosterone. In: Textbook of vascular medicine. Springer, Cham, pp 103\u2013115"},{"key":"50_CR75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","volume":"48","author":"M MacKinnon","year":"2006","unstructured":"MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48:8\u201320","journal-title":"Am J Kidney Dis"},{"key":"50_CR76","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","volume":"90","author":"V Malek","year":"2017","unstructured":"Malek V, Gaikwad AB (2017) Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications? Biomed Pharmacother 90:752\u2013759","journal-title":"Biomed Pharmacother"},{"key":"50_CR77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/cvr\/cvy226","volume":"115","author":"V Malek","year":"2019","unstructured":"Malek V, Gaikwad AB (2019) Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy. Cardiovasc Res 115:373\u2013384","journal-title":"Cardiovasc Res"},{"key":"50_CR78","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.pharep.2019.05.008","volume":"71","author":"V Malek","year":"2019","unstructured":"Malek V, Sharma N, Gaikwad AB (2019a) Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy. Pharmacol Rep 71:958\u2013967","journal-title":"Pharmacol Rep"},{"key":"50_CR79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","volume":"221","author":"V Malek","year":"2019","unstructured":"Malek V, Sharma N, Sankrityayan H, Gaikwad AB (2019b) Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy. Life Sci 221:159\u2013167","journal-title":"Life Sci"},{"key":"50_CR80","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","volume":"34","author":"S Mangiafico","year":"2013","unstructured":"Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC (2013) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34:886\u2013893c","journal-title":"Eur Heart J"},{"key":"50_CR81","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","volume":"134","author":"JF Mann","year":"2001","unstructured":"Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Inter Med 134:629\u2013636","journal-title":"Ann Inter Med"},{"key":"50_CR82","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547\u2013553","journal-title":"Lancet"},{"key":"50_CR83","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.kint.2019.05.028","volume":"96","author":"A Marquez","year":"2019","unstructured":"Marquez A, Batlle D (2019) Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone? Kidney Int 96:815\u2013817","journal-title":"Kidney Int"},{"key":"50_CR84","unstructured":"Mckelvey M, Koulis C, Krishnaswamy P, & Steckelings (2014). The effect of C21 on diabetic nephropathy progression via At2r activation. Nephrology 19: 57\u201357"},{"key":"50_CR85","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","volume":"17","author":"JJ McMurray","year":"2015","unstructured":"McMurray JJ (2015) Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail 17:242\u2013247","journal-title":"Eur J Heart Fail"},{"key":"50_CR86","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/HYPERTENSIONAHA.118.12012","volume":"73","author":"LM Meems","year":"2019","unstructured":"Meems LM, Andersen IA, Pan S, Harty G, Chen Y, Zheng Y et al (2019) Design, synthesis, and actions of an innovative bispecific designer peptide: NPA7. Hypertension 73:900\u2013909","journal-title":"Hypertension"},{"key":"50_CR87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(94)01292-9","volume":"357","author":"R Metzger","year":"1995","unstructured":"Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D (1995) Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 357:27\u201332","journal-title":"FEBS Lett"},{"key":"50_CR88","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.kint.2018.06.006","volume":"94","author":"T Micakovic","year":"2018","unstructured":"Micakovic T, Papagiannarou S, Clark E, Kuzay Y, Abramovic K, Peters J et al (2018) The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus. Kidney Int 94:937\u2013950","journal-title":"Kidney Int"},{"key":"50_CR89","doi-asserted-by":"crossref","first-page":"F437","DOI":"10.1152\/ajprenal.1999.277.3.F437","volume":"277","author":"N Miyata","year":"1999","unstructured":"Miyata N, Park F, Li XF, Cowley AW Jr (1999) Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol Renal Physiol 277:F437\u2013F446","journal-title":"Am J Physiol Renal Physiol"},{"key":"50_CR90","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000188645","volume":"70","author":"S Mizuiri","year":"1995","unstructured":"Mizuiri S, Hemmi H, Inoue A, Yoshikawa H, Tanegashima M, Fushimi T et al (1995) Angiotensin-converting enzyme polymorphism and development of diabetic nephropathy in non-insulin-dependent diabetes mellitus. Nephron 70:455\u2013459","journal-title":"Nephron"},{"key":"50_CR91","doi-asserted-by":"crossref","first-page":"e9196","DOI":"10.7717\/peerj.9196","volume":"8","author":"M Mohany","year":"2020","unstructured":"Mohany M, Alanazi AZ, Alqahtani F, Belali OM, Ahmed MM, Al-Rejaie SS (2020) LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-\u03baB mediated inflammation and glomerulosclerosis in rats. PeerJ 8:e9196","journal-title":"PeerJ"},{"key":"50_CR92","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1113\/jphysiol.2014.272328","volume":"592","author":"C Mora-Fern\u00e1ndez","year":"2014","unstructured":"Mora-Fern\u00e1ndez C, Dom\u00ednguez-Pimentel V, de Fuentes MM, G\u00f3rriz JL, Mart\u00ednez-Castelao A, Navarro-Gonz\u00e1lez JF (2014) Diabetic kidney disease: from physiology to therapeutics. J Physiol 592:3997\u20134012","journal-title":"J Physiol"},{"key":"50_CR93","doi-asserted-by":"crossref","first-page":"F812","DOI":"10.1152\/ajprenal.00655.2013","volume":"306","author":"J Mori","year":"2014","unstructured":"Mori J, Patel VB, Ramprasath T, Alrob OA, DesAulniers J, Scholey JW et al (2014) Angiotensin 1\u20137 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 306:F812\u2013F821","journal-title":"Am J Physiol Renal Physiol"},{"key":"50_CR94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/HYPERTENSIONAHA.110.163519","volume":"57","author":"LG Navar","year":"2011","unstructured":"Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA (2011) Intratubular renin-angiotensin system in hypertension. Hypertension 57:355\u2013362","journal-title":"Hypertension"},{"key":"50_CR95","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/dc09-0429","volume":"32","author":"SE Nielsen","year":"2009","unstructured":"Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS et al (2009) Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 32:1684\u20131688","journal-title":"Diabetes Care"},{"key":"50_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1043-2760(99)00205-2","volume":"11","author":"S Nouet","year":"2000","unstructured":"Nouet S, Nahmias C (2000) Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 11:1\u20136","journal-title":"Trends Endocrinol Metab"},{"key":"50_CR97","unstructured":"Ocaranza MP, Riquelme JA, Garc\u00eda L, Jalil JE, Chiong M, Santos RA et al (2019) Counter-regulatory renin\u2013angiotensin system in cardiovascular disease. Nat Rev Cardiol:1\u201314"},{"key":"50_CR98","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/hr.2010.250","volume":"34","author":"S Ogawa","year":"2011","unstructured":"Ogawa S, Nako K, Okamura M, Senda M, Mori T, Ito SJHR (2011) Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertens Res 34:400\u2013401","journal-title":"Hypertens Res"},{"key":"50_CR99","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/db09-1218","volume":"59","author":"GY Oudit","year":"2010","unstructured":"Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J et al (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59:529\u2013538","journal-title":"Diabetes"},{"key":"50_CR100","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/01.HYP.30.5.1238","volume":"30","author":"R Ozono","year":"1997","unstructured":"Ozono R, Wang Z-Q, Moore AF, Inagami T, Siragy HM, Carey RM (1997) Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 30:1238\u20131246","journal-title":"Hypertension"},{"key":"50_CR101","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M, Claggett B, Lefkowitz MP, McMurray JJ, Rouleau JL, Solomon SD et al (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 6:547\u2013554","journal-title":"Lancet Diabetes Endocrinol"},{"key":"50_CR102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejphar.2017.09.036","volume":"815","author":"A Pandey","year":"2017","unstructured":"Pandey A, Gaikwad AB (2017a) AT2 receptor agonist compound 21: a silver lining for diabetic nephropathy. Eur J Pharmacol 815:251\u2013257","journal-title":"Eur J Pharmacol"},{"key":"50_CR103","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbrc.2017.04.134","volume":"487","author":"A Pandey","year":"2017","unstructured":"Pandey A, Gaikwad AB (2017b) Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis. Biochem Biophys Res Commun 487:827\u2013833","journal-title":"Biochem Biophys Res Commun"},{"key":"50_CR104","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"H-H Parving","year":"2008","unstructured":"Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. New Engl J Med 358:2433\u20132446","journal-title":"New Engl J Med"},{"key":"50_CR105","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm4061325","volume":"4","author":"MV Perez-Gomez","year":"2015","unstructured":"Perez-Gomez MV, Sanchez-Ni\u00f1o MD, Sanz AB, Mart\u00edn-Cleary C, Ruiz-Ortega M, Egido J et al (2015) Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade. J Clin Med 4:1325\u20131347","journal-title":"J Clin Med"},{"key":"50_CR106","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","volume":"73","author":"F Persson","year":"2008","unstructured":"Persson F, Rossing P, Schjoedt K, Juhl T, Tarnow L, Stehouwer C et al (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73:1419\u20131425","journal-title":"Kidney Int"},{"key":"50_CR107","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","volume":"32","author":"F Persson","year":"2009","unstructured":"Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C et al (2009) Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32:1873\u20131879","journal-title":"Diabetes Care"},{"key":"50_CR108","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.07590810","volume":"6","author":"F Persson","year":"2011","unstructured":"Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving H-H (2011) Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 6:1025\u20131031","journal-title":"Clin J Am Soc Nephrol"},{"key":"50_CR109","doi-asserted-by":"publisher","unstructured":"Persson P, Fasching A, Palm F (2019) Acute intrarenal angiotensin (1-7) infusion decreases diabetes-induced glomerular hyperfiltration but increases kidney oxygen consumption in the rat. Acta Physiol. https:\/\/doi.org\/10.1111\/apha.13254","DOI":"10.1111\/apha.13254"},{"key":"50_CR110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-6175.2002.01506.x","volume":"4","author":"TG Pickering","year":"2002","unstructured":"Pickering TG (2002) The rise and fall of omapatrilat. J Clin Hypertens 4:371\u2013373","journal-title":"J Clin Hypertens"},{"key":"50_CR111","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/ki.2009.61","volume":"75","author":"SV Pinheiro","year":"2009","unstructured":"Pinheiro SV, Ferreira AJ, Kitten GT, Da Silveira KD, Da Silva DA, Santos SH et al (2009) Genetic deletion of the angiotensin-(1\u20137) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75:1184\u20131193","journal-title":"Kidney Int"},{"key":"50_CR112","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.numecd.2019.07.017","volume":"29","author":"G Pugliese","year":"2019","unstructured":"Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G et al (2019) Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on \u201cThe natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function\u201d. Nutr Metab Cardiovasc Dis 29:1127\u20131150","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"50_CR113","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","volume":"62","author":"Y Qi","year":"2013","unstructured":"Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M et al (2013) Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension 62:746\u2013752","journal-title":"Hypertension"},{"key":"50_CR114","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/hr.2010.235","volume":"34","author":"LA Rabelo","year":"2011","unstructured":"Rabelo LA, Alenina N, Bader M (2011) ACE2\u2013angiotensin-(1\u20137)\u2013Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 34:154\u2013160","journal-title":"Hypertens Res"},{"key":"50_CR115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jphs.2019.09.014","volume":"142","author":"A Rahman","year":"2020","unstructured":"Rahman A, Sherajee SJ, Rafiq K, Kobara H, Masaki T, Nakano D et al (2020) The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats. J Pharmacol Sci 142:124\u2013126","journal-title":"J Pharmacol Sci"},{"key":"50_CR116","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00060793-199806000-00005","volume":"5","author":"WE Rainey","year":"1998","unstructured":"Rainey WE, White P (1998) Functional adrenal zonation and regulation of aldosterone biosynthesis. Curr Opin Endocrinol Diabetes Obes 5:175\u2013182","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"50_CR117","doi-asserted-by":"publisher","unstructured":"Rajapaksha IG, Mak KY, Huang P, Burrell LM, Angus PW, Herath CB (2018) The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice. Sci Rep 8. https:\/\/doi.org\/10.1038\/s41598-41018-28490-y","DOI":"10.1038\/s41598-41018-28490-y"},{"key":"50_CR118","doi-asserted-by":"publisher","first-page":"PA926","DOI":"10.1183\/13993003","volume":"46","author":"A Rathinasabapathy","year":"2015","unstructured":"Rathinasabapathy A, Horowitz A, Horton K, Steckelings U, Unger T, Sumners C et al (2015) C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction. Eur Respiratory Soc 46:PA926. https:\/\/doi.org\/10.1183\/13993003","journal-title":"Eur Respiratory Soc"},{"key":"50_CR119","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/ki.2008.497","volume":"74","author":"HN Reich","year":"2008","unstructured":"Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM (2008) Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 74:1610\u20131616","journal-title":"Kidney Int"},{"key":"50_CR120","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","volume":"124","author":"K Reidy","year":"2014","unstructured":"Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular mechanisms of diabetic kidney disease. J Clin Invest 124:2333\u20132340","journal-title":"J Clin Invest"},{"key":"50_CR121","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","volume":"383","author":"GI Rice","year":"2004","unstructured":"Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45\u201351","journal-title":"Biochem J"},{"key":"50_CR122","doi-asserted-by":"crossref","unstructured":"Ritz E, Schmieder RE, Pollock CA (2010) Renal protection in diabetes: lessons from ONTARGET\u00ae. Cardiovasc Diabetol 9:60","DOI":"10.1186\/1475-2840-9-60"},{"key":"50_CR123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2013.251","volume":"10","author":"SS Roscioni","year":"2014","unstructured":"Roscioni SS, Heerspink HJL, De Zeeuw D (2014) The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 10:77\u201387","journal-title":"Nat Rev Nephrol"},{"key":"50_CR124","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.2337\/dc11-s248","volume":"34","author":"LM Ruilope","year":"2011","unstructured":"Ruilope LM, Solini A (2011) RAS blockade for every diabetic patient: pro and con. Diabetes Care 34:S320\u2013S324","journal-title":"Diabetes Care"},{"key":"50_CR125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/1735-5362.268205","volume":"14","author":"T Safari","year":"2019","unstructured":"Safari T, Shahraki MR, Miri S, Bakhshani NM, Niazi AA, Komeili GR et al (2019) The effect of angiotensin 1-7 and losartan on renal ischemic\/reperfusion injury in male rats. Res Pharm Sci 14:441\u2013447","journal-title":"Res Pharm Sci"},{"key":"50_CR126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1527-3466.2006.00239.x","volume":"24","author":"RA Santos","year":"2006","unstructured":"Santos RA, Ferreira AJ (2006) Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1\u20137) receptor agonist. Cardiovasc Drug Rev 24:239\u2013246","journal-title":"Cardiovasc Drug Rev"},{"key":"50_CR127","doi-asserted-by":"publisher","unstructured":"Santos R, Brosnihan KB, Chappell MC, Pesquero J, Chernicky CL, Greene LJ et al (1988) Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 11. https:\/\/doi.org\/10.1161\/1101.HYP.1111.1162_Pt_1162.I1153","DOI":"10.1161\/1101.HYP.1111.1162_Pt_1162.I1153"},{"key":"50_CR128","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","volume":"100","author":"RA Santos","year":"2003","unstructured":"Santos RA, e Silva ACS, Maric C, Silva DM, Machado RP, de Buhr I et al (2003) Angiotensin-(1\u20137) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci 100:8258\u20138263","journal-title":"Proc Natl Acad Sci"},{"key":"50_CR129","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","volume":"216","author":"RA Santos","year":"2013","unstructured":"Santos RA, Ferreira AJ, Verano-Braga T, Bader M (2013) Angiotensin-converting enzyme 2, angiotensin-(1\u20137) and Mas: new players of the renin\u2013angiotensin system. J Endocrinol 216:R1\u2013R17","journal-title":"J Endocrinol"},{"key":"50_CR130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2017","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M et al (2017) The ACE2\/angiotensin-(1\u20137)\/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1\u20137). Physiol Rev 98:505\u2013553","journal-title":"Physiol Rev"},{"key":"50_CR131","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0008-6363(03)00544-3","volume":"60","author":"S Sch\u00e4fer","year":"2003","unstructured":"Sch\u00e4fer S, Linz W, Bube A, Gerl M, Huber J, K\u00fcrzel GU et al (2003) Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res 60:447\u2013454","journal-title":"Cardiovasc Res"},{"key":"50_CR132","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1073\/pnas.85.11.4095","volume":"85","author":"MT Schiavone","year":"1988","unstructured":"Schiavone MT, Santos R, Brosnihan KB, Khosla MC, Ferrario CM (1988) Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci 85:4095\u20134098","journal-title":"Proc Natl Acad Sci"},{"key":"50_CR133","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/dom.12583","volume":"18","author":"B Schievink","year":"2016","unstructured":"Schievink B, Kr\u00f6pelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J et al (2016) Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes Metab 18:64\u201371","journal-title":"Diabetes Obes Metab"},{"key":"50_CR134","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"K Schjoedt","year":"2004","unstructured":"Schjoedt K, Andersen S, Rossing P, Tarnow L, Parving H-H (2004) Aldosterone escape during blockade of the renin\u2013angiotensin\u2013aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47:1936\u20131939","journal-title":"Diabetologia"},{"key":"50_CR135","doi-asserted-by":"crossref","first-page":"116796","DOI":"10.1016\/j.lfs.2019.116796","volume":"235","author":"N Sharma","year":"2019","unstructured":"Sharma N, Malek V, Mulay SR, Gaikwad AB (2019) Angiotensin II type 2 receptor and angiotensin-converting enzyme 2 mediate ischemic renal injury in diabetic and non-diabetic rats. Life Sci 235:116796","journal-title":"Life Sci"},{"key":"50_CR136","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.phrs.2016.03.018","volume":"107","author":"AC Sim\u00f5es E Silva","year":"2016","unstructured":"Sim\u00f5es E Silva AC, Teixeira MM (2016) ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res 107:154\u2013162","journal-title":"Pharmacol Res"},{"key":"50_CR137","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1358\/mf.2010.32.1.1434160","volume":"32","author":"T Singh","year":"2010","unstructured":"Singh T, Singh K, Sharma P (2010) Ameliorative potential of angiotensin1-7\/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats. Methods Find Exp Clin Pharmacol 32:19\u201325","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"50_CR138","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11010-012-1489-2","volume":"373","author":"Y Singh","year":"2013","unstructured":"Singh Y, Singh K, Sharma P (2013a) Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA\u2013salt-induced hypertension in rats. Mol Cell Biochem 373:189\u2013194","journal-title":"Mol Cell Biochem"},{"key":"50_CR139","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11010-012-1489-2","volume":"373","author":"Y Singh","year":"2013","unstructured":"Singh Y, Singh K, Sharma P (2013b) Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA\u2013salt-induced hypertension in rats. Mol Cell Biochem 373:189\u2013194","journal-title":"Mol Cell Biochem"},{"key":"50_CR140","doi-asserted-by":"crossref","first-page":"R1461","DOI":"10.1152\/ajpregu.00014.2007","volume":"293","author":"HM Siragy","year":"2007","unstructured":"Siragy HM, Inagami T, Carey RM (2007) NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol 293:R1461\u2013R1467","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"50_CR141","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ahj.2004.09.056","volume":"150","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M et al (2005) Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat versus Enalapril randomized trial of utility in reducing events (OVERTURE) echocardiographic study. Am Heart J 150:257\u2013262","journal-title":"Am Heart J"},{"key":"50_CR142","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.cardfail.2015.06.158","volume":"21","author":"S Solomon","year":"2015","unstructured":"Solomon S, Packer M, Zile M, Swedberg K, Rouleau J, Lefkowitz M et al (2015) The angiotensin receptor Neprilysin inhibitor LCZ696 is effective across the spectrum of ejection fraction in heart failure with reduced ejection fraction. J Card Fail 21:S45\u2013S46","journal-title":"J Card Fail"},{"key":"50_CR143","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.ajkd.2013.10.050","volume":"63","author":"RC Stanton","year":"2014","unstructured":"Stanton RC (2014) Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis 63:S3\u2013S21","journal-title":"Am J Kidney Dis"},{"key":"50_CR144","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coph.2015.01.004","volume":"21","author":"C Sumners","year":"2015","unstructured":"Sumners C, de Kloet AD, Krause EG, Unger T, Steckelings UM (2015) Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr Opin Pharmacol 21:115\u2013121","journal-title":"Curr Opin Pharmacol"},{"key":"50_CR145","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.bbapap.2013.08.008","volume":"1834","author":"M Suski","year":"2013","unstructured":"Suski M, Olszanecki R, Stachowicz A, Madej J, Bujak-Gi\u017cycka B, Oko\u0144 K et al (2013) The influence of angiotensin-(1\u20137) Mas receptor agonist (AVE 0991) on mitochondrial proteome in kidneys of apoE knockout mice. BBA-Proteins Proteom 1834:2463\u20132469","journal-title":"BBA-Proteins Proteom"},{"key":"50_CR146","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1470320311402109","volume":"12","author":"Z Tan","year":"2011","unstructured":"Tan Z, Wu J, Ma H (2011) Regulation of angiotensin-converting enzyme 2 and Mas receptor by Ang-(1\u20137) in heart and kidney of spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 12:413\u2013419","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"50_CR147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/HYPERTENSIONAHA.119.12873","volume":"74","author":"J Tang","year":"2019","unstructured":"Tang J, Wysocki J, Ye M, Vall\u00e9s PG, Rein J, Shirazi M et al (2019) Urinary renin in patients and mice with diabetic kidney disease. J Hypertens 74:83\u201394","journal-title":"J Hypertens"},{"key":"50_CR148","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1291\/hypres.25.287","volume":"25","author":"M Taniguchi","year":"2002","unstructured":"Taniguchi M, Kim S, Zhan Y, Iwao H (2002) Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. Hypertens Res 25:287\u2013294","journal-title":"Hypertens Res"},{"key":"50_CR149","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","volume":"275","author":"SR Tipnis","year":"2000","unstructured":"Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238\u201333243","journal-title":"J Biol Chem"},{"key":"50_CR150","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/HJH.0000000000002326","volume":"38","author":"E Uijl","year":"2020","unstructured":"Uijl E, C\u2018t Hart D, Roksnoer LC, Clahsen-van Groningen MC, van Veghel R, Garrelds IM et al (2020) Angiotensin\u2013neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury. J Hypertens 38:755\u2013764","journal-title":"J Hypertens"},{"key":"50_CR151","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1099-0844(200001\/03)18:1<23::AID-CBF843>3.0.CO;2-0","volume":"18","author":"B Ust\u00fcnda\u011f","year":"2000","unstructured":"Ust\u00fcnda\u011f B, Canatan H, Cinkilin\u00e7 N, Halifeo\u011flu I, Bah\u00e7ecio\u011flu IH (2000) Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. Cell Biochem Funct 18:23\u201328","journal-title":"Cell Biochem Funct"},{"key":"50_CR152","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","volume":"277","author":"C Vickers","year":"2002","unstructured":"Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277:14838\u201314843","journal-title":"J Biol Chem"},{"key":"50_CR153","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B et al (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 17:510\u2013517","journal-title":"Eur J Heart Fail"},{"key":"50_CR154","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm049715t","volume":"47","author":"Y Wan","year":"2004","unstructured":"Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam A, Wu X et al (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47:5995\u20136008","journal-title":"J Med Chem"},{"key":"50_CR155","doi-asserted-by":"crossref","first-page":"F254","DOI":"10.1152\/ajprenal.2001.280.2.F254","volume":"280","author":"GJ Wehbi","year":"2001","unstructured":"Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD (2001) Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 280:F254\u2013F265","journal-title":"Am J Physiol Renal Physiol"},{"key":"50_CR156","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T et al (2018) Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 94:567\u2013581","journal-title":"Kidney Int"},{"key":"50_CR157","first-page":"29","volume":"8","author":"R Yacoub","year":"2015","unstructured":"Yacoub R, Campbell KN (2015) Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis 8:29\u201340","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"50_CR158","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","volume":"17","author":"M Ye","year":"2006","unstructured":"Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D (2006) Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17:3067\u20133075","journal-title":"J Am Soc Nephrol"},{"key":"50_CR159","doi-asserted-by":"crossref","first-page":"e70775","DOI":"10.1371\/journal.pone.0070775","volume":"8","author":"C Zanchi","year":"2013","unstructured":"Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D et al (2013) Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One 8:e70775","journal-title":"PLoS One"},{"key":"50_CR160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ki.2014.274","volume":"87","author":"K Zhang","year":"2015","unstructured":"Zhang K, Meng X, Li D, Yang J, Kong J, Hao P et al (2015a) Angiotensin (1\u20137) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade. Kidney Int 87:359\u2013369","journal-title":"Kidney Int"},{"key":"50_CR161","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/ars.2014.6070","volume":"23","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Liu J, Luo J-Y, Tian XY, Cheang WS, Xu J et al (2015b) Upregulation of angiotensin (1-7) mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. Antioxid Redox Signal 23:880\u2013892","journal-title":"Antioxid Redox Signal"},{"key":"50_CR162","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1046\/j.1523-1755.2000.00416.x","volume":"58","author":"J Zimpelmann","year":"2000","unstructured":"Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG et al (2000) Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 58:2320\u20132330","journal-title":"Kidney Int"}],"container-title":["Reviews of Physiology, Biochemistry and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/112_2020_50","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:19:30Z","timestamp":1622506770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/112_2020_50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030742881","9783030742898"],"references-count":162,"URL":"https:\/\/doi.org\/10.1007\/112_2020_50","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-030-74289-8","asserted-by":"object"}]},"ISSN":["0303-4240","1617-5786"],"issn-type":[{"value":"0303-4240","type":"print"},{"value":"1617-5786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"27 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}